Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, placebo controlled, two-way cross-over study to explore the effects of 7 days of dosing with SYN115 20 mg p.o. bid or 60 mg p.o. bid on clinical and fMRI response to intravenous levodopa in patients with mild to moderate Parkinson's disease

Next Previous
X
Search
Trial Profile

A randomized, double-blind, placebo controlled, two-way cross-over study to explore the effects of 7 days of dosing with SYN115 20 mg p.o. bid or 60 mg p.o. bid on clinical and fMRI response to intravenous levodopa in patients with mild to moderate Parkinson's disease

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Aug 2017

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tozadenant (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Sponsors Synosia Therapeutics

    • Most Recent Events

    • 13 Jun 2010 Perfusion MRI results presented at the 14th International Congress of Parkinson's Disease and Movement Disorders.
    • 14 Apr 2010 Perfusion MRI results presented at the 62nd Annual Meeting of the American Academy of Neurology.
    • 14 Apr 2010 Results presented at 62nd Annual Meeting of the American Academy of Neurology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top